

## NEW AGREEMENT WITH MERCK: EMEND FOR INJECTION

Oncology Associates is pleased to announce a new agreement with Merck for Emend for Injection (fosaprepitant dimeglumine). The agreement will run from July 1, 2008 through June 30, 2010. Each 115 mg dose is available in 10 mL glass vials. OA members in good standing will have the opportunity to earn a 3% discount on purchases of this product.



EMEND, in combination with other antiemetic agents, is indicated for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin; and for prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

The product can be ordered through FloridaInfusion at 800-624-0152. Please contact Oncology Associates at 888-732-7352 with questions regarding this agreement.

Product	NDC #	Prod. No.	Size
EMEND for Injection (fosaprepitant dimeglumine)	0006-3884-32	3884	One 115 mg dose per 10 mL glass vial, one vial per carton

### Medicare Information for Emend for Injection

This information is current as of June 2008.

When prescribing EMEND® for Injection (fosaprepitant dimeglumine)

#### EMEND for Injection—Eligible for Medicare Part B coverage when:

- Considered to be of the type of injectable drug that is not usually self-administered,  
*and*
- Considered to be incident to a physician's services,  
*and*
- Reasonable and necessary for diagnosis or treatment of the illness or injury for which it is administered

Check with your local carrier or A/B MAC for applicable policies and procedures.

EMEND for Injection (115 mg) may be substituted for EMEND 30 minutes before chemotherapy, on Day 1 only, as an infusion administered over 15 minutes.

Visit [www.emendforinjection.com](http://www.emendforinjection.com) for full prescribing information.

## IN OTHER NEWS

### Pharmion Corporation Acquired by Celgene

Pharmion Corporation has been acquired by Celgene. Oncology Associates' agreements for Vidaza (azacitidine for injection) and Innohep (tinzaparin sodium injection) will remain unchanged.

### MGI PHARMA, Inc. Acquired by Eisai

MGI PHARMA, INC. and its subsidiaries have become a wholly-owned subsidiary of Eisai Corporation of North America. The company will now be known as Eisai. Oncology Associates' agreements for Dacogen® (decitabine) for Injection and Aloxi® (palonosetron hydrochloride) Injection will remain unchanged.